Inhibrx Inc logo

INBX

Inhibrx Inc

$20.62

Earnings Summary

Revenue
$0.92Mn
Net Profits
$-31.25Mn
Net Profit Margins
-3415.74%

Highlights

Revenue:

Inhibrx Inc’s revenue jumped 2.92% since last year same period to $0.92Mn in the Q1 2022. On a quarterly growth basis, Inhibrx Inc has generated -67.74% fall in its revenue since last 3-months.

Net Profits:

Inhibrx Inc’s net profit fell -62.03% since last year same period to $-31.25Mn in the Q1 2022. On a quarterly growth basis, Inhibrx Inc has generated -47.5% fall in its net profits since last 3-months.

Net Profit Margins:

Inhibrx Inc’s net profit margin fell -57.43% since last year same period to -3415.74% in the Q1 2022. On a quarterly growth basis, Inhibrx Inc has generated -357.17% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Inhibrx Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.78
EPS Estimate Current Year
-0.78

Highlights

EPS Estimate Current Quarter:

Inhibrx Inc’s earning per share (EPS) estimates for the current quarter stand at -0.78 - a -30% fall from last quarter’s estimates.

EPS Estimate Current Year:

Inhibrx Inc’s earning per share (EPS) estimates for the current year stand at -0.78.

Key Ratios

Key ratios of the Inhibrx Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.8
Return on Assets (ROA)
-0.38
Return on Equity (ROE)
-5.62
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Inhibrx Inc’s earning per share (EPS) fell -56.86% since last year same period to -0.8 in the Q1 2022. This indicates that the Inhibrx Inc has generated -56.86% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Inhibrx Inc’s return on assets (ROA) stands at -0.38.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Inhibrx Inc’s return on equity (ROE) stands at -5.62.

Dividend Per Share (DPS):

Inhibrx Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.6
-0.8
-33.33%

Company Information

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi.

Organisation
Inhibrx Inc
Headquarters
La Jolla, California, US
Employees
88
Industry
Health Technology